Product Reports Resources Pricing Login Book a demo

Vilya

Biotech & Life Sciences · Seattle, United States · Founded 2022

Developing a novel class of drugs that precisely target the biology of disease MoreLess

Vilya is a computational biotechnology company developing a new class of medicines.

The company's platform is based on research from the Institute of Protein Design and utilizes advanced computational methods for drug design. This technology enables the creation of novel medicines that can precisely target the biological basis of diseases.

Vilya has secured significant investment, recently expanding its Series A financing to $71 million. This capital is intended to advance the development of its computational platform and accelerate its pipeline of therapeutic candidates. The business model focuses on creating a new class of medicines to address a range of diseases, potentially through internal development or partnerships within the pharmaceutical industry.

Keywords: computational biotechnology, drug design, drug discovery, protein design, disease targeting, novel medicines, biopharmaceuticals, therapeutics, molecular design, Series A

Company overview

Vilya company information

The essential company record, classifications and operating signals in one place.

Status
Operational
Founded
2022
Headquarters
Seattle, United States
Employees
48
Open positions
3
Dealroom signal
73.1
client focusb2btechnologyArtificial IntelligencetechnologyDeep Techsub industryPharmaceuticalsub industryBioTechnologybusiness modelManufacturingindustryHealthsectorBiotechnologysectorDrug DevelopmentsectorCore AIsectorSpinoutsectorBiotech and PharmasectorGenerative AIsectorAI Drug Discovery

Valuation & funding

Vilya funding history

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Jun 2024 $21M $250M Menlo Ventures · Altitude Life Science Ventures · NVentures · Madrona Venture Group
SERIES AOther financing Aug 2022 $50M $200M ARCH Venture Partners
SPINOUTOther financing Jan 2022 $0 University of Washington Institute for Protein Design
Showing 3 recorded eventsUnlock the complete deal history →

Growth signals

Vilya website traffic

Latest recorded traffic for Vilya is 3.2K monthly website visits, down 67% over the last three months. Vilya's team declined 2% over the past year.

Latest monthly visits3.2K 3-month web change-67% 1-year team growth-2%
Monthly website visits41 observations · Oct 2022–Jun 2026
Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Vilya compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Showing 8 of the closest matchesCompare every metric →

Talent graph

Vilya's talent

Book a demo to see the people
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

7 investors on Vilya's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series A 6 investors entered at this stage
ARCH Venture Partners
Menlo Ventures
Altitude Life Science Ventures
NVentures
Madrona Venture Group
Lifeforce Capital
Other known 1 additional known investor
University of Washington Institute for Protein Design

Global footprint

Where Vilya has talent and traffic

Workforce by country
1 countries with
team presence
🇺🇸 United States97.4%
1 country shown

In the news

Latest news about Vilya

Recent press, funding announcements, and product moves mentioning Vilya — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Vilya

An AI-synthesized read of the highest-engagement posts about Vilya on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Vilya’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.